Javascript must be enabled to continue!
Focal ischemic myocardial fibrosis assessed by late gadolinium enhancement cardiovascular magnetic resonance in patients with hypertrophic cardiomyopathy
View through CrossRef
Abstract
Background
In patients with hypertrophic cardiomyopathy (HCM), ischemic myocardial fibrosis assessed by late gadolinium enhancement (I-LGE) using cardiovascular magnetic resonance (CMR) have been reported. However, the clinical significance of I-LGE has not been completely understood. We aim to evaluate the I-LGE differ phenotypically from HCM without LGE or nonischemic myocardial fibrosis assessed by late gadolinium enhancement (NI-LGE) in the left ventricle (LV).
Methods
The patients with HCM whom was underwent CMR were enrolled, using cine cardiac magnetic resonance to evaluate LV function and LGE to detect the myocardial fibrosis. Three groups were assorted: 1) HCM without LGE; 2) HCM with LGE involved the subendocardial layer was defined as I-LGE; 3) HCM with LGE not involved the subendocardial layer was defined as NI-LGE.
Results
We enrolled 122 patients with HCM in the present study. LGE was detected in 58 of 122 (48%) patients with HCM, and 22 (18%) of patients reported I-LGE. HCM with I-LGE had increased higher left ventricular mass index (LVMI) (P < 0.0001) than HCM with NI-LGE or without LGE. In addition, HCM with I-LGE had a larger LV end- systolic volume (P = 0.045), lower LV ejection fraction (LVEF) (P = 0.026), higher LV myocardial mass (P < 0.001) and thicker LV wall (P < 0.001) more than HCM without LGE alone. The I-LGE were significantly associated with LVEF (OR: 0.961; P = 0.016), LV mass (OR: 1.028; P < 0.001), and maximal end-diastolic LVWT (OR: 1.567; P < 0.001). On multivariate analysis, LVEF (OR: 0.948; P = 0.013) and maximal end-diastolic LVWT (OR: 1.548; P = 0.001) were associated with higher risk for I-LGE compared to HCM without LGE. Noticeably, the maximal end-diastolic LVWT (OR: 1.316; P = 0.011) was the only associated with NI-LGE compared to HCM without LGE.
Conclusions
I-LGE is not uncommon in patients with HCM. HCM with I-LGE was associated with significant LV hypertrophy, extensive LGE and poor LV ejection fraction. We should consider focal ischemic myocardial fibrosis when applying LGE to risk stratification for HCM.
Springer Science and Business Media LLC
Title: Focal ischemic myocardial fibrosis assessed by late gadolinium enhancement cardiovascular magnetic resonance in patients with hypertrophic cardiomyopathy
Description:
Abstract
Background
In patients with hypertrophic cardiomyopathy (HCM), ischemic myocardial fibrosis assessed by late gadolinium enhancement (I-LGE) using cardiovascular magnetic resonance (CMR) have been reported.
However, the clinical significance of I-LGE has not been completely understood.
We aim to evaluate the I-LGE differ phenotypically from HCM without LGE or nonischemic myocardial fibrosis assessed by late gadolinium enhancement (NI-LGE) in the left ventricle (LV).
Methods
The patients with HCM whom was underwent CMR were enrolled, using cine cardiac magnetic resonance to evaluate LV function and LGE to detect the myocardial fibrosis.
Three groups were assorted: 1) HCM without LGE; 2) HCM with LGE involved the subendocardial layer was defined as I-LGE; 3) HCM with LGE not involved the subendocardial layer was defined as NI-LGE.
Results
We enrolled 122 patients with HCM in the present study.
LGE was detected in 58 of 122 (48%) patients with HCM, and 22 (18%) of patients reported I-LGE.
HCM with I-LGE had increased higher left ventricular mass index (LVMI) (P < 0.
0001) than HCM with NI-LGE or without LGE.
In addition, HCM with I-LGE had a larger LV end- systolic volume (P = 0.
045), lower LV ejection fraction (LVEF) (P = 0.
026), higher LV myocardial mass (P < 0.
001) and thicker LV wall (P < 0.
001) more than HCM without LGE alone.
The I-LGE were significantly associated with LVEF (OR: 0.
961; P = 0.
016), LV mass (OR: 1.
028; P < 0.
001), and maximal end-diastolic LVWT (OR: 1.
567; P < 0.
001).
On multivariate analysis, LVEF (OR: 0.
948; P = 0.
013) and maximal end-diastolic LVWT (OR: 1.
548; P = 0.
001) were associated with higher risk for I-LGE compared to HCM without LGE.
Noticeably, the maximal end-diastolic LVWT (OR: 1.
316; P = 0.
011) was the only associated with NI-LGE compared to HCM without LGE.
Conclusions
I-LGE is not uncommon in patients with HCM.
HCM with I-LGE was associated with significant LV hypertrophy, extensive LGE and poor LV ejection fraction.
We should consider focal ischemic myocardial fibrosis when applying LGE to risk stratification for HCM.
Related Results
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Abstract
Introduction
Immunoglobulin G4-related disease (IgG4-RD) is a recently identified immune-mediated condition that is debilitating and often overlooked. While IgG4-RD has be...
Comparative Analysis of the Coronary Arteries Flow Pattern in Secondary Myocardial Hypertrophies and by Sarcomeric Mutation
Comparative Analysis of the Coronary Arteries Flow Pattern in Secondary Myocardial Hypertrophies and by Sarcomeric Mutation
Background: Coronary flow with a diastolic predominance increases two to five times in hyperemia, mediated by vasodilation (coronary flow reserve, CFR) and, in hypertrophy, relativ...
The relationship between symptom burden and myocardial fibrosis in patients with hypertrophic cardiomyopathy
The relationship between symptom burden and myocardial fibrosis in patients with hypertrophic cardiomyopathy
Abstract
Background
In hypertrophic cardiomyopathy (HCM) patients, determining the risk of sudden cardiac death and devel...
A Case of Takotsubo Cardiomyopathy Following Postpartum Hemorrhage in a Patient with Concurrent Influenza A
A Case of Takotsubo Cardiomyopathy Following Postpartum Hemorrhage in a Patient with Concurrent Influenza A
Background
Takotsubo cardiomyopathy, also known as stress cardiomyopathy and broken heart syndrome, is a transient, non-ischemic cardiomyopathy marked by revers...
Current management of hypertrophic cardiomyopathy
Current management of hypertrophic cardiomyopathy
ABSTRACT
Hypertrophic cardiomyopathy is a common yet under-recognized genetic structural heart condition characterized by left ventricular hypertrophy. Patients m...
Differentiation of Cardiac Amyloidosis and Hypertrophic Cardiomyopathy
Differentiation of Cardiac Amyloidosis and Hypertrophic Cardiomyopathy
ABSTRACT. Eriksson P, Backman C, Eriksson A, Eriksson S, Karp K, Olofsson B‐O (Departments of Internal Medicine, Geriatric Medicine, and Clinical Physiology, University Hospital, ...
[RETRACTED] Rhino XL Male Enhancement v1
[RETRACTED] Rhino XL Male Enhancement v1
[RETRACTED]Rhino XL Reviews, NY USA: Studies show that testosterone levels in males decrease constantly with growing age. There are also many other problems that males face due ...
INITIAL RESEARCH OF THE CLINICAL ROLE OF LATE GADOLINIUM ENHANCEMENT IN THE HYPERTROPHIC CARDIOMYOPATHY
INITIAL RESEARCH OF THE CLINICAL ROLE OF LATE GADOLINIUM ENHANCEMENT IN THE HYPERTROPHIC CARDIOMYOPATHY
Objectives
To investigate the correlation between clinical features and the extent of myocardial hypertrophy and late gadolinium enhancement (LGE) in hypertrophic...

